Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial

SUMMARY: BACKGROUND: In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral density (BMD)...

全面介紹

Na minha lista:
書目詳細資料
發表在:Lancet Diabetes Endocrinol
Main Authors: Tsai, Joy N, Lee, Hang, David, Natalie L, Eastell, Richard, Leder, Benjamin Z
格式: Artigo
語言:Inglês
出版: 2019
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6980341/
https://ncbi.nlm.nih.gov/pubmed/31447409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(19)30255-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍